

AMENDMENTS TO THE CLAIMS

1-54. **(Cancelled)**

55. **(Withdrawn)** A method for treating erectile dysfunction, the method comprising:
contacting a tissue surface with an effective amount of one or more
agent(s); and
applying ultrasound energy to said tissue surface, such that the erectile
dysfunction is treated.

56. **(Currently Amended)** A method for transdermal administration of one or more
agent(s) to the penile tissue surface of a subject, the method comprising:
contacting the penile tissue surface with an effective amount of one or
more agent(s); and
applying ultrasound energy to said penile tissue surface, thereby
promoting transdermal administration of one or more agent(s) to the penile tissue surface of the
subject.

57. **(Withdrawn)** A method for transdermal delivery of one or more agent(s) to the
skin of the penis, the method comprising:
contacting the penile tissue of a subject with an effective amount of one or more agent(s);
and
applying ultrasound energy to said penile tissue, thereby promoting
transdermal delivery of one or more agent(s) to the penis.

58. **(Withdrawn)** A method for promoting a penile erection, the method comprising:
contacting one or more agent(s) to the penile tissue of the subject; and
applying ultrasound to the penile tissue, thereby promoting a penile
erection.

59. **(Withdrawn)** The method of claim 55, wherein the tissue surface may be selected from the group consisting of: a skin surface of the patient, a skin surface of the penis, the glans, and the shaft of the penis.

60. **(Withdrawn)** The method of claim 55, wherein the step of contacting comprises applying the one or more agent(s) to the tissue surface with a skin patch carrying the active agent.

61. **(Withdrawn)** The method of claim 55, wherein the step of contacting comprises applying the one or more agent(s) to the tissue surface from a reservoir of the one or more agent(s) stored within a hand held applicator.

62. **(Withdrawn)** The method of claim 55, wherein the step of contacting comprises applying the one or more agent(s) to the tissue surface with a condom coated with the one or more agent(s).

63. **(Withdrawn)** The method of claim 55, wherein the agent(s) may be selected from the group consisting of: phosphodiesterase inhibitors, vasoactive agents, papaverine, minoxidil, prostaglandins, prostaglandin E2, organic nitrites, inhibitors of the renin-angiotensin system, inducible Nitric Oxide Synthase (iNOS) agents, enzyme inhibitors, sildenafil, alprostadil and smooth muscle relaxant.

64. **(Currently Amended)** A device for promoting transdermal absorption of one or more therapeutic agent(s) comprising:

an applicator for applying an effective amount of one or more agent(s) to a penile tissue surface of a subject; and

an ultrasound means, operatively coupled to the applicator, for providing ultrasound energy to the penile tissue surface that operates at one or more predetermined frequency to promote transdermal absorption of the one or more agent(s) through the penile tissue of the subject.

65. **(Withdrawn)** A device for treating erectile dysfunction, comprising:
an applicator for applying an effective amount of one or more agent(s) to
a tissue surface of a subject; and
an ultrasound means, operatively coupled to the applicator for treating
erectile dysfunction.

66. **(Original)** The device of claim 64, wherein the device further comprises a
controller for varying the frequency of the ultrasound energy.

67. **(Original)** The device of claim 64, wherein the device further comprises a
controller for varying the power of the ultrasound energy.

68. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
receptacle for drug dispensal.

C 1
69. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
skin patch carrying a pre-defined dosage of the agent(s).

70. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
condom carrying a pre-defined dosage of the agent(s).

71. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
cartridge containing a pre-defined dosage of the agent(s).

72. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
dispenser cartridge with a connector for coupling the dispenser to the transducer.

73. **(Withdrawn)** The device of claim 64, wherein the applicator further comprises a
reservoir of the agent(s) and a flow regulator for applying a pre-defined dosage of the agent(s).

74. **(Withdrawn)** The device of claim 64, wherein the device further comprises a
pressure transducer for monitoring changes in the tissue during therapy.

75. **(Withdrawn)** The device of claim 64, wherein the device further comprises a ring-like structure adapted to surround the tissue surface.

76. **(Withdrawn)** The device of claim 64, wherein the device further comprises a plurality of ultrasound transducers.

77. **(Withdrawn)** The device of claim 76, wherein the plurality of ultrasound transducers are arranged to provide constructive wave interference.

78. **(Withdrawn)** The device of claim 76, wherein the plurality of ultrasound transducers are arranged in a toroidal configuration.

79. **(Original)** The device of claim 64, wherein the device further comprises a detector for monitoring feedback signals from the transducer.

80. **(Original)** The device of claim 64, wherein the device further comprises a battery for power supply.

81. **(Original)** The device of claim 64, wherein the ultrasound means comprises a power source and at least one ultrasound transducer capable of providing ultrasound energy.

82. **(New)** A device for administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a penile tissue surface of a subject; and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the penile tissue surface at least one predetermined frequency to promote absorption of the drug through the penile tissue of the subject, wherein the ultrasound transducer further comprises at least one oscillating element capable of generating ultrasound energy at a frequency of between 100 kHz and 4 MHz.

83. (New) A device for administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a penile tissue surface of a subject, and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the penile tissue surface at least one predetermined frequency to promote absorption of the drug through the penile tissue of the subject and further comprising a pressure-sensitive switch.

84. (New) The device of either claim 82 or claim 83, wherein the ultrasound transducer further comprises at least one oscillating element capable of generating ultrasound energy at a power of about 0.02 to about 3 watts/cm².

85. (New) The device of either claim 82 or claim 83, wherein the device further comprises a controller for varying the frequency of the ultrasound energy.

86. (New) The device of either claim 82 or claim 83, wherein the device further comprises a controller for varying the power of the ultrasound energy.

87. (New) The device of either claim 82 or claim 83, wherein the device further comprises a compliant skin contacting material.

88. (New) The device of either claim 82 or claim 83, wherein the device further comprises a detector for monitoring feedback signals from the transducer.

89. (New) A device for administration of topical therapeutic agents, comprising an applicator for applying an effective amount of a therapeutic agent to a penile tissue surface of a subject, and an ultrasound transducer, operatively coupled to the applicator, for providing ultrasound energy to the penile tissue surface at least one predetermined frequency to promote absorption of the drug through the tissue of the subject, wherein the therapeutic agents are selected from the group consisting of papaverine, prostaglandin E1 (PGE 1), minoxidil, prostaglandins, organic nitrites, inhibitors of the renin-angiotensin system, inducible Nitric Oxide Synthase (iNOS) agents, and phosphodiesterase type 5 inhibitors.

90. (New) The device of claim 89, wherein the phosphodiesterase type 5 inhibitor is selected from the group consisting of sildenafil and alprostadil.

91. (New) A device for administration of topical therapeutic agents, comprising an applicator [for applying an effective amount of a therapeutic agent to a penile tissue surface of a subject] and an ultrasound transducer, operatively coupled to the applicator, [for providing ultrasound energy to the penile tissue surface at least one predetermined frequency to promote absorption of the drug through the penile tissue of the subject] wherein the therapeutic agents are selected from the group consisting of minoxidil, finasteride, fabao-101, cyproterone acetate, ethinyl estradiol, aldactone, and spironolactone.